Interferon β for Multiple Sclerosis

Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a032003. doi: 10.1101/cshperspect.a032003.


Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-β mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Clinical Trials, Phase III as Topic
  • Disease Progression
  • Humans
  • Interferon-beta / pharmacology
  • Interferon-beta / therapeutic use*
  • Medication Adherence
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Polyethylene Glycols / therapeutic use
  • Randomized Controlled Trials as Topic
  • Treatment Outcome


  • Biomarkers
  • Polyethylene Glycols
  • Interferon-beta
  • peginterferon beta-1a